Standard Biotools (LAB) Return on Capital Employed (2011 - 2026)
Standard Biotools' (LAB) quarterly Return on Capital Employed came in at 17.07% in Q1 2026, up 332.0% year-on-year from 3.95% in Q1 2025, and up 31.06% on a QoQ basis from 24.75% in Q4 2025.
Standard Biotools (LAB) Return on Capital Employed (2011 - 2026) Analysis & Trends
Standard Biotools (LAB) has 16 years of Return on Capital Employed data on file, last reported at 17.07% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 332.0% year-over-year to 17.07% in Q1 2026; TTM through Mar 2026 was 17.07%, a 332.0% increase from a year earlier, with the FY2025 full-year figure at 22.89%, up 884.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 17.07%, up from 24.75% in the prior quarter.
- Over the last five years, Return on Capital Employed for LAB reached as high as 17.07% in Q1 2026 and fell as low as 61.66% in Q1 2022.
- Historically, Return on Capital Employed has averaged 30.04% across 5 years, with a median of 25.81% in 2023.
- Across the five-year window, Return on Capital Employed tumbled 4047 bps in 2022 and surged 3044 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 32.35% in 2022, then retreated by 7 bps to 34.53% in 2023, then climbed by 29 bps to 24.65% in 2024, then slipped by 0 bps to 24.75% in 2025, then surged by 31 bps to 17.07% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 17.07% in Q1 2026, 24.75% in Q4 2025, and 25.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.03 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.82 Bn | 125.95 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 108.46 Bn | 99.24 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 68.25 Bn | 66.79 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.55 Bn | 27.43 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 28.51 Bn | 26.22 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.29 Bn | 2.07 Bn | 8.38% |
| 10 | Standard Biotools | 316.46 Mn | -138.71 Mn | 11.31 Mn | -17.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.07% |
| Dec 31, 2025 | -24.75% |
| Sep 30, 2025 | -25.36% |
| Jun 30, 2025 | -22.42% |
| Mar 31, 2025 | -20.38% |
| Dec 31, 2024 | -24.65% |
| Sep 30, 2024 | -24.11% |
| Jun 30, 2024 | -21.47% |
| Mar 31, 2024 | -28.03% |
| Dec 31, 2023 | -34.53% |
| Sep 30, 2023 | -25.81% |
| Jun 30, 2023 | -26.56% |
| Mar 31, 2023 | -31.23% |
| Dec 31, 2022 | -32.35% |
| Sep 30, 2022 | -39.62% |
| Jun 30, 2022 | -50.63% |
| Mar 31, 2022 | -61.66% |
| Sep 30, 2021 | -54.10% |
| Jun 30, 2021 | -32.03% |
| Mar 31, 2021 | -21.19% |